Trial Profile
Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High-Risk Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 17 Feb 2012 Actual patient number (45) added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.